Mallone, F.; Giustolisi, R.; Franzone, F.; Marenco, M.; Plateroti, R.; Nebbioso, M.; Lambiase, A.; Gharbiya, M.
Ten-Year Outcomes of Intravitreal Bevacizumab for Myopic Choroidal Neovascularization: Analysis of Prognostic Factors. Pharmaceuticals 2021, 14, 1042.
https://doi.org/10.3390/ph14101042
AMA Style
Mallone F, Giustolisi R, Franzone F, Marenco M, Plateroti R, Nebbioso M, Lambiase A, Gharbiya M.
Ten-Year Outcomes of Intravitreal Bevacizumab for Myopic Choroidal Neovascularization: Analysis of Prognostic Factors. Pharmaceuticals. 2021; 14(10):1042.
https://doi.org/10.3390/ph14101042
Chicago/Turabian Style
Mallone, Fabiana, Rosalia Giustolisi, Federica Franzone, Marco Marenco, Rocco Plateroti, Marcella Nebbioso, Alessandro Lambiase, and Magda Gharbiya.
2021. "Ten-Year Outcomes of Intravitreal Bevacizumab for Myopic Choroidal Neovascularization: Analysis of Prognostic Factors" Pharmaceuticals 14, no. 10: 1042.
https://doi.org/10.3390/ph14101042
APA Style
Mallone, F., Giustolisi, R., Franzone, F., Marenco, M., Plateroti, R., Nebbioso, M., Lambiase, A., & Gharbiya, M.
(2021). Ten-Year Outcomes of Intravitreal Bevacizumab for Myopic Choroidal Neovascularization: Analysis of Prognostic Factors. Pharmaceuticals, 14(10), 1042.
https://doi.org/10.3390/ph14101042